Odyssey Therapeutics, Inc. (ODTX) stock
ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026
$19.37+0.01 (+0.05%)
Close on Nov 17, 2026Market cap $930.89MP/E –Yield –
Odyssey Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$54.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.86M | – |
See a number that looks wrong?